Excessive reactive oxygen species (ROS) promotes the oxidative stress of keratinocytes, eventually causing cell damage. The natural bromophenol bis (2,3,6-tribromo-4,5-dihydroxybenzyl) ether (BTDE) from marine red algae has been reported to have a varied bioactivity; however, its antioxidant effect has yet to be investigated systemically. Our present work aimed to explore the antioxidant effect of BTDE both on the molecular and cellular models and also to illustrate the antioxidant mechanisms. Our results showed that BTDE could effectively scavenge ABTS free radicals and protect HaCaT cells from damage induced by H2O2. Mechanism studies in HaCaT cells demonstrated that BTDE attenuated hydrogen peroxide (H2O2)-induced ROS production, reduced the malondialdehyde (MDA) level, decreased the oxidized glutathione (GSSG)/glutathione (GSH) ratio, and increased the antioxidant enzyme superoxide dismutase (SOD). Moreover, BTDE could inhibit the expression of Kelch-like epichlorohydrin-associated protein 1 (Keap1) and increase the expression of both nuclear factor erythroid 2-related factor 2 (Nrf2) and its downstream proteins TrXR1, HO-1, and NQO1. BTDE also activated the upstream signaling pathway of Nrf2 such as AKT pathway, while not activating the ERK or AMPKα pathways. In general, BTDE is a promising antioxidant to protect HaCaT cells against oxidative damage via Nrf2-mediated pathways.
BCR-ABL oncoprotein drives the initiation, promotion, and progression of chronic myelogenous leukemia (CML). Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. A novel promising therapeutic strategy for CML therapy is to degrade BCR-ABL using small molecules. Antioxidant xanthohumol (XN) is a hop-derived prenylated flavonoid with multiple bioactivities. In this study, we showed XN could inhibit the proliferation, induce S phase cell cycle arrest, and stimulate apoptosis in K562 cells. XN degraded BCR-ABL in a concentration- and time-dependent manner, and the involved degradation pathway was caspase activation, while not autophagy induction or ubiquitin proteasome system (UPS) activation. Moreover, we revealed for the first time that XN could inhibit the UPS and autophagy in K562 cells, and the inhibitory effect of XN on autophagy could attenuate imatinib-induced autophagy and enhance the therapeutic efficiency of imatinib in K562 cells. Our present findings identified XN act as a degrader of BCR-ABL in K562 cells, and XN had potential to be developed as an alternate agent for CML therapy.
Brefeldin A (1), a potent cytotoxic natural macrolactone, was produced by the marine fungus Penicillium sp. (HS-N-29) from the medicinal mangrove Acanthus ilicifolius. Series of its ester derivatives 2–16 were designed and semi-synthesized, and their structures were characterized by spectroscopic methods. Their cytotoxic activities were evaluated against human chronic myelogenous leukemia K562 cell line in vitro, and the preliminary structure–activity relationships revealed that the hydroxy group played an important role. Moreover, the monoester derivatives exhibited stronger cytotoxic activity than the diester derivatives. Among them, brefeldin A 7-O-2-chloro-4,5-difluorobenzoate (7) exhibited the strongest inhibitory effect on the proliferation of K562 cells with an IC50 value of 0.84 µM. Further evaluations indicated that 7 induced cell cycle arrest, stimulated cell apoptosis, inhibited phosphorylation of BCR-ABL, and thereby inactivated its downstream AKT signaling pathway. The expression of downstream signaling molecules in the AKT pathway, including mTOR and p70S6K, was also attenuated after 7-treatment in a dose-dependent manner. Furthermore, molecular modeling of 7 docked into 1 binding site of an ARF1–GDP-GEF complex represented well-tolerance. Taken together, 7 had the potential to be served as an effective antileukemia agent or lead compound for further exploration.
Rationale: Acute hepatitis B virus (HBV) infection is clinically characterized by hepatic inflammation and parenchymal injury. As a systemic viral infection, HBV can reduce peripheral blood cell counts via suppressing bone marrow hematopoiesis. Agranulocytosis is defined as severe neutropenia, with an absolute neutrophil count below 0.5 × 10 9 /L. Standardized diagnostic and therapeutic protocols for HBV-associated agranulocytosis have not been established in clinical practice guidelines. Particularly, antiviral therapy in reversing HBV-induced bone marrow dysfunction remains to be fully elucidated. This case report aims to describe this clinical entity and elucidate the potential benefits of timely early antiviral intervention. Patient concerns: A 51-year-old female patient presented with unexplained fatigue persisting for over 20 days, coupled with anorexia and dysgeusia for greasy food. Diagnoses: Acute HBV infection complicated with neutropenia, confirmed by follow-up comprehensive evaluations after the initial laboratory findings of marked elevation of liver enzymes and leukopenia. Interventions: The patient received liver protection therapy with phosphatidylcholine and magnesium isoglycyrrhizinate, as well as supportive care to stimulate leukocyte production. Due to persistent leukopenia and detectable elevation of HBV deoxyribonucleic acid, entecavir was initiated for antiviral treatment. Outcomes: The above abnormal symptoms were relieved after antiviral therapy. Liver function and neutrophil counts returned to normal levels, and HBV deoxyribonucleic acid levels decreased significantly. Hepatitis B surface antigen seroconversion was achieved normal level after 6 months; therefore, clinical treatment was successfully discontinued. Follow-up showed sustained virologic and hematologic remission. Lessons: This case highlights acute HBV infection as a causative factor for severe neutropenia/agranulocytosis. Importantly, the study reveals that early antiviral treatment can not only suppress viral replication but also reverse bone marrow suppression, leading to complete hematologic recovery and functional cure (hepatitis B surface antigen seroconversion). This study demonstrates that antiviral therapy is necessary for the management of acute HBV with severe hematologic complications.